TransViragen Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • TransViragen's estimated annual revenue is currently $2.6M per year.(i)
  • TransViragen's estimated revenue per employee is $155,000

Employee Data

  • TransViragen has 17 Employees.(i)
  • TransViragen grew their employee count by 6% last year.

TransViragen's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Senior Scientist at TransViragen, IncReveal Email/Phone
3
Assistant ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.2M72-13%N/AN/A
#2
$5099.8M32902-4%N/AN/A
#3
$1.7M110%N/AN/A
#4
$0.6M4-56%N/AN/A
#5
$0.9M11-39%N/AN/A
#6
$1.7M1110%N/AN/A
#7
$0.6M4-33%N/AN/A
#8
$4.8M31-6%N/AN/A
#9
$6.4M413%N/AN/A
#10
$4.2M27-18%N/AN/A
Add Company

What Is TransViragen?

TransViragen is a privately held Biotechnology company based in Research Triangle Park, NC that specializes in the production of genetically modified mice, rats and cell lines. TransViragen offers a full suite of custom model generation services that includes the design, generation and characterization of transgenic, BAC transgenic, knockout and knock-in rodent models. With an emphasis on high quality, unparalleled customer service and timeliness, TransViragen provides clients with flexible options to meet their specific project needs, from individual services to full-service model development options. TransViragen’s services are accompanied by the most comprehensive guarantees in the industry, and clients retain full intellectual property rights to their models. TransViragen’s growing client-base includes investigators in academic, pharmaceutical, biotechnology and government institutions worldwide.

keywords:N/A

N/A

Total Funding

17

Number of Employees

$2.6M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.6M18100%N/A
#2
$2.8M18-10%N/A
#3
$2.1M2111%N/A
#4
$3.4M220%N/A
#5
$2.3M230%N/A